XBIO Xenetic Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$2.24
· of 52w range
· above low
· to high
$1.8752w low
$13.9352w high
Market Cap (MRQ)
$5M
P/E (TTM)
-1.9
EPS (TTM)
$-1.15
Revenue (TTM)
$3M
your badges
52W Range
$2–$14
Analyst Rating
HOLD
Price Target
·
P/E
-1.9
ROE
-47.0%
Net Profit Margin
-75.9%
Your badge strip is empty — pin a metric anywhere on this page.
XBIO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.24
Market Cap (MRQ)
$5M
P/E (TTM)
-1.9
EPS (TTM)
$-1.15
Revenue (TTM)
$3M
ROE (TTM)
-47.0%
52W Range
$2–$14
XBIO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| May 15, 2023 | 1-for-10 | Reverse |
| June 25, 2019 | 1-for-12 | Reverse |
About Xenetic Biosciences, Inc. - Common Stock Company overview from Wikipedia
sectorHealthcare
industryBiotechnology
employees2
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$3M2016-12-31 → 2025-12-31
EPS$-1.582021-12-31 → 2025-12-31
Net margin-75.9%
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | XBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -1.95Y avg ≈-5.7 | ≈-5.7 | · | · | |
| P/S (TTM) | 1.6 | · | 175.2 | Undervalued | |
| P/B (MRQ) | 0.9 | · | 1.1 | Overvalued | |
| Price / Tangible Book | 0.75Y avg ≈3.0 | ≈3.0 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | XBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -81.0% | · | -66598.4% | Top tier | |
| Net Profit Margin (TTM) | -75.9% | · | -66722.3% | Top tier | |
| ROA (TTM) | -40.2% | · | -82.8% | Top tier | |
| ROE (TTM) | -47.0% | · | -102.2% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | XBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 7.4 | · | 2.6 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | XBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 19.0%5Y avg ≈55.8% | ≈55.8% | · | · | |
| Revenue CAGR 3Y | 20.4%5Y avg ≈43.1% | ≈43.1% | · | · | |
| Revenue CAGR 5Y | 46.8% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | XBIO | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$1.5M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-69.7%
Next Report
Nov 10, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2025 | $-0.45 | $-0.65 | 31.1% | |
| March 31, 2025 | $-0.59 | $-0.73 | 19.7% | |
| Dec. 31, 2024 | $-0.68 | $-0.20 | -233.3% | |
| Sept. 30, 2024 | $-0.28 | $-0.14 | -96.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $3M | $3M | $2M | $1M | $436.9K | $17.1K | $0 | $8M | $3M | $0 | $0 | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| R&D Expense | $3M | $3M | $3M | $5M | $3M | $2M | $5M | $3M | $4M | $44M | $3M | $6M | |
| SG&A Expense | $3M | $3M | $4M | $4M | $4M | $3M | $5M | $4M | $7M | $7M | $6M | $7M | |
| Operating Expenses | $6M | $7M | $7M | $8M | $7M | $14M | $13M | $7M | · | · | · | $13M | |
| Operating Income | $-3M | $-4M | $-5M | $-7M | $-6M | $-14M | $-13M | $-7M | $-4M | $-47M | $-10M | $-13M | |
| Interest Expense | · | · | · | · | · | · | · | · | $1.8K | $729.6K | $267.0K | $4.7K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $19.0K | |
| Other Non-op | $5.7K | $-5.7K | $25.4K | $-1.6K | $1.1K | $-492 | $3.3K | $-24.6K | $-24.6K | $-85.4K | $-235.4K | $-326.9K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-14M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $-3M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-4M | $-7M | $-6M | $-11M | $-13M | $-7M | $-4M | $-54M | $-13M | $-14M | |
| EPS (Basic) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | · | · | · | · | · | · | · | |
| Shares (Basic) | 1,701,571 | 1,541,339 | 1,528,210 | 1,422,443 | 10,279,408 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 1,701,571 | 1,541,339 | 1,528,210 | 1,422,443 | 10,279,408 | · | · | · | · | · | · | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8M | $6M | $9M | $13M | $18M | $12M | $10M | $571.6K | $6M | $4M | $132.2K | $3M | |
| Receivables | · | · | · | · | · | · | · | · | $0 | $3M | $0 | · | |
| Prepaid Expense | $166.3K | $422.0K | $603.8K | $556.1K | $479.4K | $842.0K | $722.1K | $555.9K | $285.0K | $1M | $247.3K | $204.0K | |
| Current Assets | $8M | $7M | $10M | $14M | $19M | $12M | $11M | $1M | $6M | $8M | $4M | $3M | |
| PP&E (Net) | · | · | · | $0 | $0 | $0 | $757 | $5.0K | $27.8K | $42.4K | $62.0K | $119.4K | |
| PP&E (Gross) | · | · | · | $0 | $50.2K | $57.0K | $57.0K | $89.4K | $358.3K | $349.1K | $332.3K | $586.1K | |
| Accum. Depreciation | · | · | · | $0 | $50.2K | $57.0K | $56.3K | $84.4K | $330.5K | $306.7K | $270.2K | $466.7K | |
| Goodwill | · | · | · | · | · | $0 | $9M | $3M | $3M | $3M | $3M | $3M | |
| Other Non-current Assets | $313.9K | $313.9K | $1M | $1M | $1M | $810.0K | $1M | $705.7K | $724.7K | $66.3K | $129.3K | $199.3K | |
| Total Assets | $8M | $7M | $11M | $15M | $20M | $13M | $22M | $14M | $19M | $21M | $17M | $16M | |
| Accounts Payable | $258.1K | $283.6K | $240.8K | $287.4K | $362.5K | $327.4K | $931.1K | $934.1K | $786.8K | $1M | $2M | $852.8K | |
| Accrued Liabilities | $709.9K | $610.6K | $568.8K | $785.8K | $1M | $574.0K | $464.0K | $664.0K | $1M | $838.9K | $1M | $1M | |
| Current Liabilities | $968.0K | $894.3K | $809.6K | $1M | $1M | $936.9K | $1M | $2M | $2M | $2M | $7M | $3M | |
| Capital Leases | · | · | · | · | · | $27.0K | $0 | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | $27.0K | $3M | $3M | $3M | $3M | $3M | $3M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $0 | $0 | $19.9K | $38.8K | $56.4K | |
| Total Liabilities | $968.0K | $894.3K | $809.6K | $1M | $1M | $964.0K | $4M | $5M | $5M | $5M | $10M | $6M | |
| Common Stock | $2.3K | $1.5K | $1.5K | $1.5K | $13.5K | $8.8K | $6.1K | $811 | $9.0K | $8.7K | $4.9K | $150.0K | |
| Paid-in Capital | $212M | $208M | $208M | $208M | $206M | $194M | $188M | $168M | $165M | $164M | $100M | $91M | |
| Retained Earnings | $-200M | $-197M | $-193M | $-189M | $-183M | $-177M | $-166M | $-153M | $-146M | $-142M | $-88M | $-76M | |
| Treasury Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| AOCI | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $575.7K | |
| Stockholders' Equity | $7M | $6M | $10M | $14M | $18M | $12M | $17M | $10M | $14M | $16M | $7M | $10M | |
| Liabilities + Equity | $8M | $7M | $11M | $15M | $20M | $13M | $22M | $14M | $19M | $21M | $17M | $16M | |
| Shares Outstanding | 2,291,056 | 1,542,139 | 1,540,684 | 1,516,659 | 13,439,612 | 8,745,207 | 6,065,441 | 783,865 | 8,717,541 | 4,585,800 | 4,585,800 | 139,297,282 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | $0 | $0 | $1.0K | · | · | · | · | $56.1K | $88.7K | |
| Stock-based Comp | $64.8K | $171.8K | $283.1K | $511.5K | $410.4K | $468.9K | $806.1K | $1M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $-2M | $-3M | $-4M | $-5M | $-5M | $-4M | $-6M | $-6M | $1M | $-9M | $-5M | $-13M | |
| CapEx | · | · | · | · | · | · | · | $0 | $9.3K | $16.8K | $1.7K | $57.7K | |
| Investing Cash Flow | · | · | $0 | $-500.0K | $0 | $0 | $2.0K | $22.5K | $-9.3K | $-16.8K | · | · | |
| Stock Issued | $4M | $0 | · | $0 | $11M | $5M | $0 | · | · | · | $0 | $10M | |
| Financing Cash Flow | $4M | $0 | · | $0 | $11M | $5M | $16M | $1M | $0 | $13M | · | · | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | · | $0 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 | · | · | · | · | · | · | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 19.0% | -1.6% | 48.8% | 47.1% | 165.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 20.4% | 29.1% | 79.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 46.8% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3M | $3M | $3M | $2M | $1M | $436.9K | $17.1K | $0 | $8M | $3M | $0 | $0 | |
| Net Income TTM | $-3M | $-4M | $-4M | $-7M | $-6M | $-11M | $-13M | $-7M | $-4M | $-54M | $-13M | $-14M | |
| P/E | -1.4 | -1.6 | -1.3 | -0.6 | -23.5 | · | · | · | · | · | · | · | |
| P / Tangible Book | 0.7 | 1.0 | 0.5 | 3.2 | 9.4 | 14.6 | · | · | · | · | · | · | |
| Earnings Yield | -72.8% | -64.4% | -78.5% | -161.8% | -4.3% | · | · | · | · | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $660.6K | $806.9K | $766.3K | $1M | $589.9K | $593.3K | $648.8K | $614.2K | $726.4K | $510.8K | $672.0K | $611.2K | $651.0K | $605.8K | $487.0K | $414.2K | |
| R&D Expense | $552.0K | $661.4K | $773.4K | $756.5K | $656.6K | $879.0K | $1M | $368.0K | $933.8K | $944.3K | $975.6K | $1M | $903.2K | $595.3K | $1M | $398.8K | |
| SG&A Expense | $1M | $647.6K | $615.9K | $815.2K | $657.8K | $656.6K | $705.7K | $745.7K | $1M | $834.9K | $952.0K | $737.2K | $946.0K | $925.7K | $857.2K | $863.2K | |
| Operating Expenses | $2M | $1M | $1M | $2M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Operating Income | $-971.7K | $-502.1K | $-623.0K | $-544.7K | $-724.4K | $-942.4K | $-1M | $-499.5K | $-1M | $-1M | $-1M | $-1M | $-1M | $-915.2K | $-2M | $-847.8K | |
| Interest Income | $42.1K | $45.8K | · | · | $34.2K | $39.2K | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $-72 | $-21 | $159 | $4.0K | $1.5K | $78 | $-7.2K | $1.5K | $-21 | $52 | $404 | $-666 | $21.1K | $4.5K | $986 | $-1.7K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-929.7K | $-456.4K | $-579.1K | $-509.9K | $-688.7K | $-903.1K | $-1M | $-436.7K | $-1M | $-1M | $-1M | $-1M | $-1M | $-856.6K | $-1M | $-804.0K | |
| EPS (Basic) | $-0.41 | $-0.20 | $-0.21 | $-0.33 | $-0.45 | $-0.59 | $-0.68 | $-0.28 | $-0.83 | $-0.78 | $-0.77 | $-0.69 | $-0.69 | $-0.56 | $-2.03 | $-0.56 | |
| EPS (Diluted) | $-0.41 | $-0.20 | $-0.21 | $-0.33 | $-0.45 | $-0.59 | $-0.68 | $-0.28 | $-0.83 | $-0.78 | $-0.77 | $-0.69 | $-0.69 | $-0.56 | $-2.03 | $-0.56 | |
| Shares (Basic) | 2,294,364 | 2,291,056 | · | 1,542,139 | 1,542,139 | 1,542,139 | · | 1,541,722 | 1,540,799 | 1,540,684 | · | 1,532,600 | 1,524,717 | 1,516,659 | · | 1,431,659 | |
| Shares (Diluted) | 2,294,364 | 2,291,056 | · | 1,542,139 | 1,542,139 | 1,542,139 | · | 1,541,722 | 1,540,799 | 1,540,684 | · | 1,532,600 | 1,524,717 | 1,516,659 | · | 1,431,659 | |
| EBITDA | · | $-502.1K | · | $-544.7K | $-724.4K | $-942.4K | · | $-499.5K | $-1M | $-1M | · | $-1M | $-1M | $-915.2K | · | $-847.8K |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | $7M | · | · | · | $5M | · | $7M | $7M | $8M | $9M | $10M | $11M | $12M | $13M | $14M | |
| Prepaid Expense | $182.3K | $247.8K | $166.3K | $946.4K | $573.9K | $313.6K | $422.0K | $188.1K | $716.4K | $552.0K | $603.8K | $1M | $1M | $876.5K | $556.1K | $319.1K | |
| Current Assets | $7M | $8M | $8M | $5M | $5M | $5M | $7M | $7M | $8M | $8M | $10M | $11M | $12M | $13M | $14M | $14M | |
| Other Non-current Assets | $313.9K | $313.9K | $313.9K | $0 | $0 | $313.9K | $313.9K | $1M | $1M | $1M | $1M | $704.4K | $704.4K | $844.4K | $1M | $1M | |
| Total Assets | $7M | $8M | $8M | $5M | $5M | $6M | $7M | $8M | $9M | $9M | $11M | $12M | $13M | $14M | $15M | $16M | |
| Accounts Payable | $322.5K | $558.8K | $258.1K | $578.2K | $346.8K | $240.3K | $283.6K | $243.3K | $283.6K | $210.5K | $240.8K | $448.6K | $221.3K | $259.2K | $287.4K | $202.8K | |
| Accrued Liabilities | · | · | $709.9K | · | · | · | $610.6K | · | · | · | $568.8K | · | · | · | $785.8K | · | |
| Current Liabilities | $895.0K | $958.2K | $968.0K | $1M | $903.4K | $667.9K | $894.3K | $1M | $2M | $716.5K | $809.6K | $1M | $871.3K | $856.4K | $1M | $1M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Total Liabilities | $895.0K | $958.2K | $968.0K | $1M | $903.4K | $667.9K | $894.3K | $1M | $2M | $716.5K | $809.6K | $1M | $871.3K | $856.4K | $1M | $1M | |
| Common Stock | $2.3K | $2.3K | $2.3K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K | $15.2K | $1.5K | $14.3K | |
| Paid-in Capital | $212M | $212M | $212M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $208M | $207M | |
| Retained Earnings | $-201M | $-200M | $-200M | $-199M | $-199M | $-198M | $-197M | $-196M | $-196M | $-194M | $-193M | $-192M | $-191M | $-190M | $-189M | $-188M | |
| Treasury Stock | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| AOCI | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | $253.7K | |
| Stockholders' Equity | $6M | $7M | $7M | $4M | $4M | $5M | $6M | $7M | $7M | $9M | $10M | $11M | $12M | $13M | $14M | $15M | |
| Liabilities + Equity | $7M | $8M | $8M | $5M | $5M | $6M | $7M | $8M | $9M | $9M | $11M | $12M | $13M | $14M | $15M | $16M | |
| Shares Outstanding | 2,343,181 | 2,293,757 | 2,291,056 | 1,542,139 | 1,542,139 | 1,542,139 | 1,542,139 | 1,542,139 | 1,541,101 | 1,540,684 | 1,540,684 | 1,532,600 | 1,532,600 | 15,166,596 | 1,516,659 | 14,316,596 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $52.0K | $11.3K | $14.0K | $15.9K | $15.7K | $19.3K | $25.1K | $27.5K | $42.1K | $77.1K | $74.6K | $70.3K | $69.4K | $68.9K | $118.7K | $137.4K | |
| Operating Cash Flow | $-875.5K | $-536.4K | $-242.7K | $-658.2K | $-383.8K | $-1M | $-674.0K | $-459.0K | $-525.1K | $-1M | $-793.0K | $-949.6K | $-1M | $-1M | $-750.9K | $-1M | |
| Investing Cash Flow | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | $0 |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -62.2% | · | -53.0% | -122.8% | -158.8% | · | -81.3% | -184.1% | -248.3% | · | -187.6% | -184.1% | -151.1% | · | -204.7% | |
| Net Margin | · | -56.6% | · | -49.7% | -116.8% | -152.2% | · | -71.1% | -175.4% | -234.0% | · | -172.7% | -161.4% | -141.4% | · | -194.1% | |
| EBITDA Margin | · | -62.2% | · | -53.0% | -122.8% | -158.8% | · | -81.3% | -184.1% | -248.3% | · | -187.6% | -184.1% | -151.1% | · | -204.7% | |
| ROA | · | -6.7% | · | -7.8% | -9.6% | -11.9% | · | -4.4% | -11.7% | -10.3% | · | -7.7% | -7.2% | -5.4% | · | -4.4% | |
| ROE | · | -7.6% | · | -9.3% | -11.6% | -13.1% | · | -4.9% | -13.2% | -11.1% | · | -8.3% | -7.8% | -5.8% | · | -4.6% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 7.9 | · | 4.6 | 5.9 | 8.2 | · | 7.0 | 5.0 | 11.7 | · | 10.5 | 13.8 | 15.0 | · | 13.5 | |
| Quick Ratio | · | 7.7 | · | · | · | 7.7 | · | 6.8 | 4.6 | 10.9 | · | 9.1 | 12.3 | 14.0 | · | 13.2 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $3.03 | · | $2.57 | $2.89 | $3.32 | · | $4.56 | $4.83 | $5.63 | · | $7.11 | $7.75 | $0.85 | · | $1.01 | |
| Revenue / Share | · | $0.35 | · | $0.67 | $0.38 | $0.38 | · | $0.40 | $0.47 | $0.33 | · | $0.40 | $0.43 | $0.04 | · | $0.03 | |
| Cash Flow / Share | · | $-0.23 | · | · | · | $-0.65 | · | · | · | $-0.75 | · | · | · | $-0.07 | · | · | |
| Cash / Share | · | $3.20 | · | · | · | $3.35 | · | $4.44 | $4.74 | $5.08 | · | $6.38 | $7.00 | $0.79 | · | $0.97 | |
| EPS (TTM) | $-1.39 | $-1.19 | · | $-2.05 | $-2.00 | $-2.38 | · | $-2.66 | $-3.07 | $-2.93 | · | $-3.97 | $-3.84 | $-5.05 | · | $-2.72 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3M | $3M | · | $3M | $2M | $3M | · | $3M | $3M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Net Income TTM | $-2M | $-2M | · | $-3M | $-3M | $-4M | · | $-4M | $-5M | $-4M | · | $-4M | $-4M | $-6M | · | $-7M | |
| Market Cap | · | $6M | · | $5M | $6M | $4M | · | $7M | $6M | $6M | · | $8M | $5M | $62M | · | $77M | |
| P/E | -2.5 | -2.3 | · | -1.5 | -2.0 | -1.1 | · | -1.6 | -1.3 | -1.3 | · | -1.2 | -0.9 | -0.8 | · | -2.0 | |
| P/S | 2.1 | 1.9 | · | 1.7 | 2.5 | 1.6 | · | 2.6 | 2.5 | 2.4 | · | 3.2 | 2.3 | 32.0 | · | 49.5 | |
| P/B | 1.1 | 0.9 | · | 1.2 | 1.4 | 0.8 | · | 0.9 | 0.8 | 0.7 | · | 0.7 | 0.4 | 4.8 | · | 5.3 | |
| P / Tangible Book | 1.1 | 0.9 | · | 1.2 | 1.4 | 0.8 | · | 0.9 | 0.8 | 0.7 | · | 0.7 | 0.4 | 4.8 | · | 5.3 | |
| P / Cash Flow | · | -11.5 | · | · | · | -4.0 | · | · | · | -5.0 | · | · | · | -55.9 | · | · | |
| Earnings Yield | -39.5% | -44.4% | · | -65.3% | -51.0% | -91.2% | · | -61.6% | -75.4% | -77.7% | · | -81.0% | -117.1% | -124.4% | · | -50.6% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $3M | $3M | $3M | $2M | $1M |
| Net Income | $-3M | $-4M | $-4M | $-7M | $-6M |
| Diluted EPS | $-1.58 | $-2.57 | $-2.71 | $-4.61 | $-0.55 |
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 8 filers · $435K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
8
Value held
$435K
New positions
2
Exited positions
0
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 2 (+1 vs prior Q) | 0 (-5 vs prior Q) | 1 (0 vs prior Q) | 3 (+1 vs prior Q) | -17K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $341,750 | 117,440 | 78.61% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $50,723 | 17,423 | 11.67% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $36,902 | 12,681 | 8.49% | Shares |
| SBI Securities Co., Ltd. | $2,910 | 1,000 | 0.67% | Shares |
| Tower Research Capital LLC (TRC) | $2,025 | 696 | 0.47% | Shares |
| MORGAN STANLEY | $437 | 150 | 0.10% | Shares |
| JTC Employer Solutions Trustee Ltd | $8 | 2,700 | 0.00% | Shares |
| Darwin Wealth Management, LLC | $5 | 2 | 0.00% | Shares |
Activists & 5%+ owners 3 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| CLS Therapeutics, LLC, CLS Therapeutics Ltd., Dmitry Genkin, Victor Tets, Georgy Tets, M. Scott Maguire ×3 filings | March 18, 2024 | · | Initial filing | Passive investment | SEC |
| PJSC Pharmsynthez, LLC SynBio, Dmitry Genkin | July 13, 2017 | · | Initial filing | · | SEC |
| Michael Scott Maguire | Nov. 22, 2016 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 14 insiders · 4 officers · 12 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| James F Parslow | Interim CEO and CFO | April 21, 2026 A | 100,000 | 0 | 0 | $0 |
| Jeffrey F Eisenberg | Chief Executive Officer | Dec. 11, 2023 A | 50,000 | 0 | 0 | $0 |
| Michael Scott Maguire | CEO | Dec. 20, 2016 A | · | 0 | 0 | $0 |
| Curtis Lockshin | Chief Sciencific Officer | Dec. 11, 2023 A | · | 0 | 0 | $0 |
| Grigory G. Borisenko | Director | Dec. 31, 2025 A | · | 0 | 0 | $0 |
| Alexey Andreevich Vinogradov | Director | Dec. 31, 2025 A | · | 0 | 0 | $0 |
| Firdaus J. Dastoor | Director | Dec. 31, 2025 A | · | 0 | 0 | $0 |
| Roger D. Kornberg | Director | Dec. 31, 2025 A | · | 0 | 0 | $0 |
| Moshe Mizrahy | Director | Dec. 6, 2023 A | · | 0 | 0 | $0 |
| James Eric Callaway | Director | Dec. 6, 2023 A | · | 0 | 0 | $0 |
| Adam Logal | Director | Dec. 6, 2023 A | · | 0 | 0 | $0 |
| Dmitry Genkin | Director | July 19, 2019 A | 93,603 | 0 | 0 | $0 |
| Edward J. Benz JR | Director | Dec. 20, 2016 A | · | 0 | 0 | $0 |
| Darlene M Deptula-Hicks | Director | Dec. 20, 2016 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 1 ETF
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0.00% | 12,681 SH | Aug. 19, 2026 | Daily |
XBIO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 6 analysts
SELL
0 0.0%
Strong Buy
0 0.0%
Buy
3 50.0%
Hold
1 16.7%
Sell
2 33.3%
Strong Sell
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026